skip to main content

PET-CT in Myositis Cancer — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardMyositisPET-CT in Myositis CancerSCE Rheumatology

A patient with high-risk anti-TIF1-gamma dermatomyositis has negative conventional enhanced malignancy screening but persistent weight loss and treatment-resistant disease. What additional test may be considered?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Whole-body FDG PET-CT after review of the unresolved cancer risk

In high-risk IIM with unrevealing conventional screening, whole-body FDG PET-CT can be considered, especially when strong clinical suspicion persists. It supplements rather than automatically replaces sex-specific and organ-directed screening.

Reference: IMACS international guideline for inflammatory-myopathy-associated cancer screening (Published November 2023): https://www.nature.com/articles/s41584-023-01045-w; BSR guideline for idiopathic inflammatory myopathy in children and adults (Published April 2022): https://academic.oup.com/rheumatology/article/61/5/1760/6555980